Tofacitinib for the treatment of moderate-to-severe psoriasis

Expert Rev Clin Immunol. 2015 Apr;11(4):443-55. doi: 10.1586/1744666X.2015.1013534. Epub 2015 Feb 10.


Because of the increased knowledge about the underlying cytokine network in psoriasis, selective systemic agents for the treatment of moderate-to-severe psoriasis have been developed during the past decade. The marked upregulation of JAK/STAT pathways in psoriasis and the identification of multiple key mediators in psoriasis pathogenesis that signal through JAK/STAT pathways led to investigation of JAK proteins as potential therapeutic targets for psoriasis treatment. A novel JAK-STAT inhibitor, tofacitinib, has been tested in preclinical studies for the treatment of psoriasis. Considering the satisfactory safety profile and the encouraging efficacy observed in the Phase II and Phase III trials, tofacitinib may represent an important therapeutic to be included into the psoriasis paradigm.

Keywords: IL-23; Th17; psoriasis; small molecules; tofacitinib.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Disease Progression
  • Humans
  • Janus Kinases / antagonists & inhibitors
  • Molecular Targeted Therapy
  • Piperidines / pharmacology
  • Piperidines / therapeutic use*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*
  • Pyrroles / pharmacology
  • Pyrroles / therapeutic use*
  • STAT Transcription Factors / antagonists & inhibitors


  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Pyrroles
  • STAT Transcription Factors
  • tofacitinib
  • Janus Kinases